Anvesha
Anvesha™
Decoding Plant Intelligence
{{ l.label }}
Click to skip
Anvesha
Anvesha™ Decoding Plant Intelligence
{{ menuGlyph }}
Enquire about profiling
{{ m.label }}
Enquire about profiling
Anvesha™ Intel · a six-vertical multi-omics screening platform

Decoding medicinal biodiversity into evidence.

Anvesha™ is the first AI-integrated platform to profile Indian herbal biodiversity across genomics, proteomics, metabolomics and ecological data, establishing scientific validation for herbal therapeutics at reference-grade quality.

Request a profiling proposal
Explore the Atlas →
The gap
7,000+
medicinal plant species in India
~1,500
listed in a pharmacopeia

Four out of five Indian medicinal species have no molecular reference standard. Anvesha™ is building it.

{{ s.v }}
{{ s.k }}

Phase I cohort

Select a species for its Atlas record
{{ c.common }}
{{ c.latin }}
{{ c.cue }}
01 / Anvesha™ Intel

Six verticals, one screening platform.

Anvesha™ Intel is our screening platform. Each vertical answers a different question about a herb; read together they constitute a molecular identity and a mechanism, reproducible, auditable and defensible before a regulator.

See all six verticals →
{{ l.n }}

{{ l.title }}

{{ l.scope }}

{{ c }}
02 / The Atlas

One record per herb. Every layer in one place.

The Anvesha™ database holds authenticated identity, chemical fingerprints, functional omics signatures and safety readouts for each profiled species, searchable, exportable, API-accessible, and FAIR by design.

Open the interactive preview
ANVESHA™ / RECORD PREVIEW
{{ r.label }}
{{ r.v }}
03 / Services

What we run for partners.

Executed with Althea DRF Lifesciences under OECD GLP, ISO and AAALAC-compliant conditions.

{{ s.n }}

{{ s.title }}

{{ s.body }}

Profiling a herb, or a whole portfolio?

Tell us the species, the therapeutic indication and the regulatory destination. We will come back with a scope, a timeline and a deliverable list.

Start an enquiry →
Anvesha™ Intel

Anvesha™ Intel: six screening verticals, read as one signature.

Transcriptomics, genomics, metabolomics, pathway mapping, target identification and contextual tissue-specific screens, run on the same authenticated material and fused by AI.

{{ v.n }}

{{ v.title }}

{{ v.scope }}

Example
{{ v.example }}
{{ c }}
See all six verticals run end to end on Simarouba glauca →

Technologies & instrumentation

The platforms behind each capability.

{{ t.name }}

{{ t.body }}

{{ k }}
Workflow

Ten steps from raw herb to validated record.

Select a step to see its objective, method and outputs.

{{ st.num }} {{ st.title }}
Step {{ active.num }}

{{ active.title }}

{{ active.objective }}

Method & outputs
{{ p }}
← Previous
Next step →
Anvesha™ Atlas · v2.0 preview build

The Atlas of Integrated Diversity.

One queryable record per species, holding authenticated identity, chemical fingerprints, functional omics signatures and safety readouts, held together under FAIR principles.

{{ s.v }}
{{ s.k }}
◈ANVESHA™ / ATLAS
›
{{ v.label }}
System
{{ f.label }}
Sort
{{ o.label }}
SpeciesG · P · M · SCoverageStatus
{{ h.common }} {{ h.id }}
{{ h.latin }}
{{ c.v }}
{{ h.cov }}
{{ h.status }}
Coverage matrix · species × omics layer
{{ m }} {{ h.common }}
{{ c.v }}
NOT PROFILED
REFERENCE GRADE
{{ resultCount }} {{ queryEcho }}
No matching records

This preview holds a sample of the Phase I cohort. Reset the query, or request the full dataset.

RESET
REQUEST DATASET
{{ selected.id }} {{ selected.status }}

{{ selected.common }}

{{ selected.latin }}

{{ selected.note }}

All six verticals run in full Case study →
Omics coverage mean {{ selected.cov }}
{{ b.n }}
{{ b.v }}
Marker compounds
{{ m }}
Implicated pathways
{{ p }}
{{ m.k }} {{ m.v }}
REQUEST FULL DATASET
API · CSV · FAIR
Anvesha™ Intel · reference case · ANV-0007

Simarouba glauca, read across all six verticals.

Multi-omics evaluation of Simarouba glauca liquid extract in MDA-MB-231 triple-negative breast cancer cells. Genome-wide transcriptomics and untargeted metabolomics, run on one authenticated extract and read together to name a mechanism rather than a single hit.

{{ c }}

Study conducted jointly by Althea DRF Lifesciences and Genotypic Technology (P) Ltd · for CIMR · July 2026

Material on record
Leaf and seed kernel · Karnataka, Tamil Nadu, Andhra Pradesh · 29 authenticated accessions · liquid extract
{{ s.v }}
{{ s.k }}

What ran, vertical by vertical

Anvesha™ Intel · 6 / 6 complete
{{ v.n }} COMPLETE
{{ v.t }}
{{ v.b }}
V/01 · Transcriptomics

Extensive transcriptomic reprogramming, not a single hit.

Top oncology-related differentially expressed genes in treated versus untreated cells, ranked by fold change. Clear separation between treated and control replicates confirmed a reproducible response.

▲ Upregulated fold change vs. control
{{ g.g }}
{{ g.fc }}
{{ g.role }}
▼ Downregulated fold change vs. control
{{ g.g }}
{{ g.fc }}
{{ g.role }}
V/05 · Target identification

Four coordinated programs.

The transcriptomic signature resolves into a multi-target effect rather than inhibition of one molecular target.

{{ p.n }}

{{ p.title }}

{{ p.body }}

{{ p.arrow }}
{{ g }}
Mechanistic axis

p53 · PTEN · PI3K / AKT / mTOR.

Three independent lines of evidence converge on one signalling axis, including the PTEN paradox and its resolution.

{{ a.k }}

{{ a.title }}

{{ r.g }} {{ r.fc }} {{ r.role }}
{{ a.out }}
Synthesis

Coordinated induction of p53-responsive suppressors (BTG2, EGR1/2) with downregulation of PI3K/mTOR drivers (PIK3CG, MSI2, MAPK3, TYMS) points to convergent growth arrest, differentiation and apoptosis across the p53–PTEN–PI3K/AKT/mTOR axis.

V/03 · Metabolomics

Untargeted UPLC-MS/MS across the full detectable metabolome.

PCA and PLS-DA both separated treated from untreated cells without supervision, so the treatment effect dominates variance in the dataset.

{{ s.v }}
{{ s.k }}
Metabolites identified per sample
{{ s.s }}
{{ s.v }}
Extreme differentially accumulated metabolites
{{ d.name }} {{ d.v }}
{{ d.dir }} · log₂ fold change
V/04 · Pathway mapping
KEGG Human library (Nov 2025), hypergeometric enrichment with relative betweenness-centrality topology. Bars show relative enrichment rank.
{{ p.t }}
Most enriched chemical classes
{{ c }}

How the two pipelines were run

Every step recorded, so the record is reproducible by a third party.

Transcriptomic pipeline
{{ s.n }}
{{ s.t }}
{{ s.b }}
Metabolomic pipeline
{{ s.n }}
{{ s.t }}
{{ s.b }}
Conclusion

The first comprehensive multi-omics read of Simarouba glauca extract in TNBC cells.

Extensive modulation of genes and metabolites governing oncogenic signalling, proliferation, metabolism and cellular stress response gives mechanistic insight into potential anticancer activity, and a foundation for preclinical validation of a multi-target therapeutic candidate.

This is the depth every Anvesha™ Intel record is built toward. The same six verticals are being applied across the Phase I cohort.

Request the full Simarouba dataset →
Open the record in the Atlas
Review the six verticals
Impact & roadmap

Built to be cited, adopted and enforced.

Anvesha™ is designed to serve four constituencies at once: science, regulation, industry and conservation.

{{ i.tag }}

{{ i.title }}

{{ i.body }}

Three-year plan

From pilot cohort to an operational global platform.

{{ p.year }}

{{ p.title }}

{{ it }}
Deliverable: {{ p.deliverable }}

Key deliverables

What exists at the end of the programme, regardless of who uses it.

{{ d.n }}
{{ d.text }}
Who we are

Scientists, regulators and operators who have done this before.

Anvesha™ is delivered with Althea DRF Lifesciences, bringing 30+ years of drug discovery and development, and 120+ herbal products registered.

{{ t.v }}
{{ t.k }}
{{ m.role }}

{{ m.name }}

{{ m.bio }}

Advisory council

Domain leadership across the five disciplines the platform depends on.

{{ a.field }}

{{ a.body }}

Execution capability

Althea DRF Lifesciences runs the workflow under OECD GLP, ISO and AAALAC-compliant conditions.

{{ c.v }}
{{ c.k }}
Talk to the scientific team →
New Delhi · 40+ countries served
Enquiries

Tell us what you need profiled.

Species, indication and regulatory destination are enough to start. We reply with scope, timeline and deliverables, typically within three working days.

{{ c.k }} {{ c.v }}
Enquiry received.

Thank you. A member of the scientific team will respond to your request within three working days.
Profiling enquiry
Services of interest
{{ c.label }}
Send enquiry

Submissions are treated as confidential. Preview build; this form does not transmit data.